top of page
deliverysystem_vignette.jpg

Groundbreaking innovation

The SpyGlass Pharma™ Drug Delivery Platform combines safe, lasting treatment with the world's most common, routine ophthalmic surgery.

Spyglass Platform Pipeline

Spyglass-Platform-Pipeline-20250321_edit
texture_bg.jpg

SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform

ALISO VIEJO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced that 18-month data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated improvements in both visual acuity and intraocular pressure (IOP) outcomes, key objectives for long-term treatment of glaucoma or ocular hypertension. The data will be highlighted in a poster presentation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 25-28, 2025, in Los Angeles. (View full press release)

Spyglass Pharma Logo - Long - Black_edited.png

Technology

Tel: 949-284-6904

About

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

Investors

CONTACT US

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Thanks for submitting!

SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer

© 2025 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

  • LinkedIn
bottom of page